ACE OncoCast
FaktaThe official podcast feed of ACE Oncology. ACE provides evidence-based, high-quality independent medical education solutions that support clinicians in making up-to-date, appropriate treatment decisions. Listen to discussions among experts and stay informed on new data and best practices in the care of patients with cancer. The information in this podcast is provided for informational and educational purposes only.
Siste episoder av ACE OncoCast podcast
- Expert Interview of Specialist Insights in Urothelial Cancer: Optimal Management for NMIBC and MIBC Patients (1 of 2) (00:12:33)
Félix Guerrero-Ramos, MD, PhD, FEBU Hospital Doce de Octubre Madrid, Spain The therapeutic landscape for urothelial cancer has undergone significant transformation in recent years, with the addition of PD1/PD-L1 targeting immune checkpoint inhibitors and novel targeted therapies and antibody-drug conjugates (ADCs) adding to the complexity of treatment options available for patients throughout the course of their disease. The optimal sequencing of treatments depends on an understanding of the...
- Expert Interview of Specialist Insights in Urothelial Cancer: Optimal Management for NMIBC and MIBC Patients (2 of 2) (00:04:10)
Natalia Carballo, MD MD Anderson Cancer Center Madrid Madrid, Spain The therapeutic landscape for urothelial cancer has undergone significant transformation in recent years, with the addition of PD1/PD-L1 targeting immune checkpoint inhibitors and novel targeted therapies and antibody-drug conjugates (ADCs) adding to the complexity of treatment options available for patients throughout the course of their disease. The optimal sequencing of treatments depends on an understanding of the relevan...
- Expert Interview of Specialist Insights in Urothelial Cancer: Highlights of the Evolving Therapeutic Landscape in Urothelial Cancer (00:24:54)
Enrique Grande, MD, MSc, PhD MD Anderson Cancer Center Madrid Madrid, Spain The therapeutic landscape for urothelial cancer has undergone significant transformation in recent years, with the addition of PD1/PD-L1 targeting immune checkpoint inhibitors and novel targeted therapies and antibody-drug conjugates (ADCs) adding to the complexity of treatment options available for patients throughout the course of their disease. The optimal sequencing of treatments depends on an understanding of the...
- Expert Interview of Specialist Insights in Urothelial Cancer: Molecular Pathology and Biology of Urothelial Cancer (00:15:17)
Francisco X. Real, MD, PhD National Cancer Research Center Madrid, Spain The therapeutic landscape for urothelial cancer has undergone significant transformation in recent years, with the addition of PD1/PD-L1 targeting immune checkpoint inhibitors and novel targeted therapies and antibody-drug conjugates (ADCs) adding to the complexity of treatment options available for patients throughout the course of their disease. The optimal sequencing of treatments depends on an understanding of the re...
- Session 2: Maximizing the survival benefit through a sequential treatment strategy in locally advanced or metastatic urothelial cancer_Episode 2 (00:20:58)
Episode 2: Case 1: Second-line and salvage treatment options after maintenance immunotherapy Case 2: Second-line and salvage treatment options after platinum-based chemotherapy Kate Smith, MBBS, MRCP, MD, PhD The increasing availability of treatment options in the first-line (1L) setting after ESMO 2023 has led to a growing complexity in determining sequential treatment strategies for different clinical scenarios following progression of 1L therapies. In this educational program on 'Best P...
- Session 2: Maximizing the survival benefit through a sequential treatment strategy in locally advanced or metastatic urothelial cancer_Episode 1 (00:21:41)
Episode 1: Opening & Keynote Speech: Second-line and salvage treatment decision-making for unresectable locally advanced or metastatic (LA/m) urothelial cancer (UC) Philippe Barthélémy, MD, PhD The increasing availability of treatment options in the first-line (1L) setting after ESMO 2023 has led to a growing complexity in determining sequential treatment strategies for different clinical scenarios following progression of 1L therapies. In this educational program on 'Best Practice Exch...
- Session 1: Reconsidering the optimization of first-line treatment strategies in locally advanced or metastatic urothelial cancer_Episode 3 (00:22:41)
Episode 3: Panel Discussion & Pearls for Practice Fernando Maluf, MD, PhD, Enrique Grande, MD, MSc, PhD and Joachim Chan, BSc, MBBS, MRCP, FRCR, MD The therapeutic landscape of unresectable locally advanced or metastatic (LA/m) urothelial cancer (UC) has undergone a significant transformation in recent years with the addition of immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 and novel antibody-drug conjugates (ADCs) to the treatment armamentarium. In real-world practice, facto...
- Session 1: Reconsidering the optimization of first-line treatment strategies in locally advanced or metastatic urothelial cancer_Episode 2 (00:23:41)
Episode 2: Case 1: First-line treatment with maintenance immunotherapy for a platinum-eligible patient Case 2: First-line treatment with mono-immunotherapy for a cisplatin-ineligible patient Joachim Chan, BSc, MBBS, MRCP, FRCR, MD The therapeutic landscape of unresectable locally advanced or metastatic (LA/m) urothelial cancer (UC) has undergone a significant transformation in recent years with the addition of immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 and novel antibody-drug...
- Session 1: Reconsidering the optimization of first-line treatment strategies in locally advanced or metastatic urothelial cancer_Episode 1 (00:26:44)
Episode 1: Opening & Keynote Speech: First-line treatment decision-making for unresectable locally advanced or metastatic (LA/m) urothelial cancer (UC) Enrique Grande, MD, MSc, PhD The therapeutic landscape of unresectable locally advanced or metastatic (LA/m) urothelial cancer (UC) has undergone a significant transformation in recent years with the addition of immune checkpoint inhibitors (ICIs) targeting PD-1/PD-L1 and novel antibody-drug conjugates (ADCs) to the treatment armamentari...
- Session 2: Maximizing the survival benefit through a sequential treatment strategy in locally advanced or metastatic urothelial cancer_Episode 3 (00:21:33)
Episode 3: Panel Discussion & Pearls for Practice Aristotelis Bamias, MD, PhD, Philippe Barthélémy, MD, PhD and Kate Smith, MBBS, MRCP, MD, PhD The increasing availability of treatment options in the first-line (1L) setting after ESMO 2023 has led to a growing complexity in determining sequential treatment strategies for different clinical scenarios following progression of 1L therapies. In this educational program on 'Best Practice Exchange in Clinical Case Scenarios', field experts wil...
- Clinical Insights on the Treatment Algorithm in Unresectable Locally Advanced or Metastatic Urothelial Cancer 4: Novel Drugs in Development (00:24:53)
The therapeutic landscape of advanced urothelial cancer has undergone a significant transformation in recent years with the addition of PD-1/PD-L1 targeting immune checkpoint inhibitors and novel antibody-drug conjugates to the treatment armamentarium. In this Clinical Insights on the Treatment Algorithm in Unresectable Locally Advanced or Metastatic Urothelial Cancer, experts in the field will discuss the latest evidence supporting the use of these therapies in clinical practice, including p...
- Clinical Insights on the Treatment Algorithm in Unresectable Locally Advanced or Metastatic Urothelial Cancer 3: Second/subsequential Treatment Decision-making (00:16:43)
The therapeutic landscape of advanced urothelial cancer has undergone a significant transformation in recent years with the addition of PD-1/PD-L1 targeting immune checkpoint inhibitors and novel antibody-drug conjugates to the treatment armamentarium. In this Clinical Insights on the Treatment Algorithm in Unresectable Locally Advanced or Metastatic Urothelial Cancer, experts in the field will discuss the latest evidence supporting the use of these therapies in clinical practice, including p...
- Clinical Insights on the Treatment Algorithm in Unresectable Locally Advanced or Metastatic Urothelial Cancer 1: First-line Treatment Decision-making (00:14:25)
The therapeutic landscape of advanced urothelial cancer has undergone a significant transformation in recent years with the addition of PD-1/PD-L1 targeting immune checkpoint inhibitors and novel antibody-drug conjugates to the treatment armamentarium. In this Clinical Insights on the Treatment Algorithm in Unresectable Locally Advanced or Metastatic Urothelial Cancer, experts in the field will discuss the latest evidence supporting the use of these therapies in clinical practice, including p...
- Clinical Insights on the Treatment Algorithm in Unresectable Locally Advanced or Metastatic Urothelial Cancer 2: First-line Maintenance Treatment Decision-making (00:20:43)
The therapeutic landscape of advanced urothelial cancer has undergone a significant transformation in recent years with the addition of PD-1/PD-L1 targeting immune checkpoint inhibitors and novel antibody-drug conjugates to the treatment armamentarium. In this Clinical Insights on the Treatment Algorithm in Unresectable Locally Advanced or Metastatic Urothelial Cancer, experts in the field will discuss the latest evidence supporting the use of these therapies in clinical practice, including p...
- Expert Interview: Frequently Asked Questions (FAQs) for Second Line (2L) and Salvage Treatments (00:10:50)
There is a steadily widening range of second-line (2L) and subsequent treatment options for patients with advanced UC including chemotherapy, immune checkpoint inhibitors (ICIs) and novel therapies. In recent years, ICIs have predominantly replaced chemotherapy as the preferred 2L treatment. Furthermore, antibody-drug conjugates (ADC) and targeted agents have become available. The selection of 2L and salvage treatments for advanced UC depends on many factors, including the initial treatment s...
- Expert Interview: Frequently Asked Questions (FAQs) for Muscle Invasive Bladder Cancer (MIBC) (00:13:53)
Muscle-Invasive Bladder Cancer (MIBC) is defined as the tumor has spread through the bladder lining and into the bladder muscle. Optimal treatment strategies for MIBC requires the involvement of a specialist multidisciplinary team (MDT), with collaboration between surgeons, medical oncologists, radiation oncologists, pathologists and other specialists. Bladder preservation is an alternative to cystectomy for patients deemed unfit for surgery. The MDT board should develop a treatment strategy...
- Expert Interview: Frequently Asked Questions (FAQs) for Non Muscle Invasive Bladder Cancer (NMIBC) (00:07:22)
About 70% to 80% of bladder cancers present as non-muscle-invasive bladder cancer (NMIBC). The management of NMIBC includes transurethral resection of bladder tumor (TURBT), followed by single-dose intravesical immunotherapy with bacille Calmette-Guérin (BCG) or intravesical chemotherapy (mitomycin C, epirubicin, or doxorubicin). The decision to instill BCG and/or chemotherapy is based on the risk of cancer progression or recurrence. For practicing oncologists, it is crucial to address Frequ...
- Expert Interview: Frequently Asked Questions (FAQs) for First Line (1L) Treatment Decision making (00:17:07)
Platinum-based chemotherapy (CT) has been the preferred treatment for patients with unresectable locally advanced and/or metastatic (LA/m) urothelial cancer (UC) for several decades. With the evolving development of immunotherapy in the first-line (1L) setting, the standard management approach for LA/m UC consisted of cisplatin-based CT in cisplatin eligible patients or carboplatin-based CT in cisplatin ineligible patients followed by maintenance avelumab (an anti-PD-L1 inhibitor) in those wh...
- Personalized therapy in SCLC: Promises and challenges (00:09:52)
In the third and final podcast on extensive-stage SCLC, the experts discuss ongoing trials, as well as potential predictive biomarkers of response, and the problem of tumor plasticity.
- Closer look at the biology of SCLC and molecular subtypes (00:10:58)
In the second podcast on extensive-stage SCLC, the experts examine the biology of SCLC and discuss the molecular subtypes, which have distinct therapeutic vulnerabilities.
- Current standard of care for ES SCLC (00:16:43)
In this first of three podcasts on extensive-stage SCLC, the experts discuss the management of patients with relapsed SCLC based on current evidence and guidelines.
- Second-line and salvage treatments for metastatic urothelial cancer (00:10:09)
In this final episode of our podcast exploring the role of immunotherapy in advanced urothelial cancer, Dr Tom Powles and Dr Aristotelis Bamias discuss the treatment options for patients after first-line or maintenance immunotherapy, including second-line immunotherapy and salvage treatment options.
- First-line treatment of advanced metastatic urothelial cancer (00:14:27)
In the first of three podcasts exploring the role of immunotherapy in advanced urothelial cancer, genitourinary cancer experts Dr Tom Powles and Dr Aristotelis Bamias discuss the latest evidence-based treatment strategies for patients with advanced metastatic urothelial cancer.
- Locally advanced disease (00:13:19)
In this second podcast, Dr Tom Powles and Dr Aristotelis Bamias discuss the role of immunotherapy in the neoadjuvant or adjuvant setting for patients with locally advanced disease, based on the latest data from clinical trials.
- Targeting KRAS G12C Mutations (00:11:56)
In this episode, the experts assess the latest data on targeted therapy for KRAS G12C-mutated NSCLC, including the first phase III data on targeted therapy. Hear expert opinions of how these results may influence clinical practice.